old
man
present
emerg
depart
erfan
niyayesh
hospit
tehran
iran
complain
highgrad
fever
cough
dyspnea
five
day
admiss
time
fever
peripher
oxygen
satur
face
mask
abnorm
seen
laboratori
result
except
posit
creactiv
protein
lymphopenia
sever
respiratori
acidosi
chest
xray
imag
reveal
bilater
infiltr
upper
lower
lob
figur
figur
also
inflammatori
cytokin
measur
hour
follow
last
session
hemoperfus
show
remark
decreas
decreas
pgml
pgml
pgml
pgml
respect
measur
also
show
decreas
pgml
pgml
tumor
necrosi
factor
alpha
level
decreas
pgml
pgml
end
session
hemoperfus
patient
final
transfer
ward
accept
clinic
condit
cytokin
cascad
patient
new
coronaviru
lead
caus
death
critic
ill
patient
varieti
blood
purif
technolog
treatment
method
crrt
plu
hemoperfus
seem
effect
certain
case
cytokin
releas
storm
probabl
phenomenon
sever
case
extracorpor
organ
support
support
vital
organ
function
heart
lung
kidney
liver
also
avoid
organ
damag
remov
excess
inflammatori
mediat
extracorpor
blood
j
u
r
n
l
p
r
e
p
r
f
purif
technolog
proven
effect
elimin
inflammatori
cytokin
crp
etc
report
success
case
repres
experi
extracorpor
blood
purif
patient
confirm
pneumonia
case
high
tocilizumab
antagonist
anoth
potenti
agent
howev
tocilizumab
therapi
may
associ
advers
effect
access
tocilizumab
limit
iran
also
tocilizumab
effect
regard
mechan
hemoperfus
impact
one
cytokin
may
effect
case
respond
hemoperfus
crrt
without
remark
complic
henc
hemoperfus
dispos
cartridg
may
promis
option
decreas
inflammatori
cytokin
induc
ard
howev
necessari
conduct
clinic
trial
find
efficaci
safeti
strategi
